Do you want to read an article? Please log in or register.
Maximal Recruitment Open Lung Ventilation in Acute Respiratory Distress Syndrome (PHARLAP): A Phase II, Multicenter, Randomized, Controlled Trial
ARDS
RECOMMENDED
Related content
ARDS
Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome: a Randomized Controlled Trial
Am J Respir Crit Care Med.
Lalgudi Ganesan S, Jayashree M, Singhi SC, Bansal A
doi: 10.1164/
RECOMMENDED
ARDS
Airway Pressure Release Ventilation in Pediatric Acute Respiratory Distress Syndrome. A Randomized Controlled Trial
Am J Respir Crit Care Med.
Lalgudi Ganesan S, Jayashree M, Chandra Singhi S, Bansal A
doi: 10.1164/rccm.
Moderate and Severe Acute Respiratory Distress Syndrome: Hemodynamic and Cardiac Effects of an Open Lung Strategy With Recruitment Maneuver Analyzed Using Echocardiography
Crit Care Med.
Mercado P, Maizel J, Kontar L, Nalos M, Huang S, Orde S, McLean A, Slama M
doi: 10.1097/CCM.
RECOMMENDED
ARDS
Sigh in patients with acute hypoxemic respiratory failure and acute respiratory distress syndrome: the PROTECTION pilot randomized clinical trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Chest
Mauri T, Foti G, Fornari C, Grasselli G, Pinciroli R, Lovisari F, Tubiolo D, Volta CA, Spadaro S, Rona R, Rondelli E, Navalesi P, Garofalo E, Knafelj R, Gorjup V, Colombo R, Cortegiani A, Zhou JX, D'Andrea R, Calamai I, González ÁV, Roca O, Grieco DL, Jovaisa T, Bampalis D, Becher T, Battaglini D, Ge H, Luz M, Constantin JM, Ranieri M, Guerin C, Mancebo J, Pelosi P, Fumagalli R, Brochard L, Pesenti A
doi: 10.1016/j.chest.2020.10.079
RECOMMENDED
ARDS
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial
★ 2
Recommended by
Dr Martin Frey, Faculty Member
JAMA.
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP, COALITION COVID-19 Brazil III Investigators
doi: 10.1001/jama.2020.17021.
RECOMMENDED
ARDS
Rapidly improving acute respiratory distress syndrome in therapeutic randomized controlled trials
Chest.
Schenck EJ, Oromendia C, Torres LK, Berlin DA, Choi AMK, Siempos II
doi: 10.1016/j.chest.2018.09.031.
RECOMMENDED
ARDS
Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial
JAMA.
Goligher EC, Tomlinson G, Hajage D, Wijeysundera DN, Fan E, Jüni P, Brodie D, Slutsky AS, Combes A
doi: 10.1001/jama.2018.14276.
ARDS
Keratinocyte growth factor for the treatment of the acute respiratory distress syndrome (KARE): a randomised, double-blind, placebo-controlled phase 2 trial
Lancet Respir Med.
McAuley DF, Cross LM, Hamid U, Gardner E, Elborn JS, Cullen KM, Dushianthan A, Grocott MP, Matthay MA, O'Kane CM
doi: 10.1016/
COMMENTED
ARDSAsthma
Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial
Lancet Respir Med.
Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Irish Critical Care Trials Group
doi: 10.1016/